CSF3 and infection: The prophylactic use of granulocyte colony-stimulating factors (G-CSF) is therefore recommended for patients at high (> 20%) or intermediate (10–20%) risk of febrile neutropenia to reduce the risk of severe, potentially life-threatening infections and hospitalization [1, 7–10].